Article thumbnail

Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings

By Rory Leisegang, Gary Maartens, Michael Hislop, Leon Regensberg and Susan Cleary
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1997). A: The assessment of refill compliance using pharmacy records: methods, validity, and applications.
  2. (2000). Adherence to triple therapy and viral load response
  3. (2009). Affordability - the forgotten criterion in health care priority setting. Health Economics
  4. (2009). Africa: Historical CPIX key indicators. STATSSA
  5. (1998). An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics
  6. (2006). Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: guidelines for a public health approach. Geneva: World Health Organization
  7. (2008). Boulle AM: Assessing efficiency and the costs of scaling-up HIV-treatment.
  8. (2006). Boulle AM: The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resourc Alloc
  9. (2009). Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis. PloS Medicine
  10. (2008). Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization
  11. (2006). Effectiveness and cost effectiveness of early and late prevention on HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care
  12. (2005). Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases
  13. (2009). Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. Health Econ
  14. (2006). et al: Cost-Effectiveness of HIV Treatment in Resource-Poor Settings - The Case of Cote d’Ivoire.
  15. (2005). et al: Predictors of HIV drug-resistance mutations in a large antiretroviralnaive cohort initiating triple antiretroviral therapy.
  16. Federal Reserve Statistical Release: Foreign Exchange Rates (Annual).
  17. (2010). Health Department approves new HIV treatment guidelines. Health-e
  18. (2000). How should cost data in pragmatic randomised trials be analysed?
  19. (1988). Inui T: A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care
  20. (2006). Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. JAIDS
  21. (2010). Maartens G: Association of Antiretroviral Therapy Adherence and Health Care Costs. Annals of Internal Medicine
  22. (1993). Markov models in medical decision making: a practical guide. Medical Decision Making
  23. (2006). Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincome countries. Lancet
  24. (2006). P: A comparison of multivariable regression models to analyse cost data.
  25. (2007). Santas C: Cost-Effectiveness of Alternative Strategies for Initiating and Monitoring Highly Active Antiretroviral Therapy in the Developing World. JAIDS
  26. The costs and benefits of private sector provision of treatment to HIV-infected employees in
  27. (2006). When to initiate HAART in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy